Clinical trials: Idarubicin
Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
This phase II trial is studying the side effects and best dose of bortezomib and to see how well it works when given together with combination chemotherapy in treating younger patients with recurrent, refractory, or secondary…
- Conditions
- Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Trial name
- NCT00666588
- Testing
- idarubicin, cytarabine, bortezomib
- Where
- 82 sites in United States, Australia and 1 more
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT02339740
- Testing
- Arsenic Trioxide, Cytarabine, Dexamethasone
- Where
- 174 sites in United States, Australia and 4 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Leukemia, Acute Myeloid Leukemia
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML.
- Conditions
- Leukemia, Acute Myeloid Leukemia, AML
- Trial name
- NCT00422591
- Testing
- Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma, Non-Hodgkin
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination…
- Trial name
- NCT02703272
- Testing
- Ibrutinib, Rituximab, Ifosfamide
- Where
- 76 sites in United States, Belgium and 18 more
- Volunteers
- 72 people
- Sponsor
- Janssen Research & Development, LLC
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the highest safe dose of vorinostat that can be given in combination with idarubicin and ara-C for the treatment of AML and high-risk MDS.
- Trial name
- NCT00656617
- Testing
- Idarubicin, Cytarabine, Vorinostat
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- M.D. Anderson Cancer Center
AML, Acute Myeloid Leukemia
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
A primary goal of this clinical research study is to find the highest safe dose of sorafenib that can be given in combination with idarubicin and Ara-C for the treatment of acute myelogenous leukemia (AML) and high-risk…
- Conditions
- AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
- Trial name
- NCT00542971
- Testing
- Idarubicin, Sorafenib, Ara-C
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
RATIONALE: Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and idarubicin, work in different ways to stop the growth of…
- Trial name
- NCT00469859
- Testing
- cytarabine, idarubicin, lestaurtinib
- Where
- 21 sites in United States
- Volunteers
- 14 people
- Sponsor
- Children's Oncology Group
Acute Promyelocytic Leukemia
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
- Trial name
- NCT00413166
- Testing
- All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- LAL0904 (NCT00458848)
- Testing
- asparaginase, daunorubicin hydrochloride, etoposide
- Where
- 66 sites in Italy
- Volunteers
- 470 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Primary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic…
- Trial name
- ISAKIDS (NCT03860844)
- Testing
- Isatuximab, Dexamethasone or equivalent, Fludarabine
- Where
- 41 sites in United States, Argentina and 14 more
- Volunteers
- 67 people
- Sponsor
- Sanofi
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT00866918
- Testing
- Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis
- Where
- 121 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Children's Oncology Group
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
This phase I/II trial is studying the side effects and best dose of tipifarnib when given with idarubicin and cytarabine and to see how well it works in treating patients with newly diagnosed myelodysplastic syndromes or acute…
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
- Trial name
- NCT00096122
- Testing
- cytarabine, idarubicin, tipifarnib
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
RATIONALE: Giving chemotherapy before an autologous stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00534469
- Testing
- aldesleukin, filgrastim, busulfan
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Leukemia
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00528398
- Testing
- cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- City of Hope Medical Center